

Markus Mitterhauser

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8700130/publications.pdf>

Version: 2024-02-01

247
papers

5,970
citations

66315

42
h-index

114418

63
g-index

275
all docs

275
docs citations

275
times ranked

7136
citing authors

#	ARTICLE	IF	CITATIONS
1	Assessment of left and right ventricular functional parameters using dynamic dual-tracer [13N]NH ₃ and [18F]FDG PET/MRI. <i>Journal of Nuclear Cardiology</i> , 2022, 29, 1003-1017.	1.4	6
2	Identification of tumor tissue-derived DNA methylation biomarkers for the detection and therapy response evaluation of metastatic castration resistant prostate cancer in liquid biopsies. <i>Molecular Cancer</i> , 2022, 21, 7.	7.9	10
3	Simultaneous radiomethylation of [11C]harmine and [11C]DASB and kinetic modeling approach for serotonergic brain imaging in the same individual. <i>Scientific Reports</i> , 2022, 12, 3283.	1.6	0
4	Experimental Nuclear Medicine Meets Tumor Biology. <i>Pharmaceuticals</i> , 2022, 15, 227.	1.7	4
5	Cyclotrons Operated for Nuclear Medicine and Radiopharmacy in the German Speaking D-A-CH Countries: An Update on Current Status and Trends. <i>Frontiers in Nuclear Medicine</i> , 2022, 2, .	0.7	3
6	Feasibility and Optimal Time Point of [68Ga]Gallium-labeled Prostate-specific Membrane Antigen Ligand Positron Emission Tomography Imaging in Patients Undergoing Cytoreductive Surgery After Systemic Therapy for Primary Oligometastatic Prostate Cancer: Implications for Patient Selection and Extent of Surgery. <i>European Urology Open Science</i> , 2022, 40, 117-124.	0.2	1
7	A Microdosing Study with ^{99m} Tc-PHC-102 for the SPECT/CT Imaging of Primary and Metastatic Lesions in Renal Cell Carcinoma Patients. <i>Journal of Nuclear Medicine</i> , 2021, 62, 360-365.	2.8	20
8	Thyroid and androgen receptor signaling are antagonized by ¹²⁵ I-Crystallin in prostate cancer. <i>International Journal of Cancer</i> , 2021, 148, 731-747.	2.3	17
9	Supervised machine learning enables non-invasive lesion characterization in primary prostate cancer with [68Ga]Ga-PSMA-11 PET/MRI. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2021, 48, 1795-1805.	3.3	72
10	Differential impact of radiation therapy after radical prostatectomy on recurrence patterns: an assessment using [68Ga]Ga-PSMA ligand PET/CT(MRI). <i>Prostate Cancer and Prostatic Diseases</i> , 2021, 24, 439-447.	2.0	0
11	Prediction of response and survival after standardized treatment with 7400ÂMBq 177Lu-PSMA-617 every 4Âweeks in patients with metastatic castration-resistant prostate cancer. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2021, 48, 1650-1657.	3.3	21
12	Association of norepinephrine transporter methylation with in vivo NET expression and hyperactivityâ€“impulsivity symptoms in ADHD measured with PET. <i>Molecular Psychiatry</i> , 2021, 26, 1009-1018.	4.1	23
13	Disrupted relationship between blood glucose and brain dopamine D2/3 receptor binding in patients with first-episode schizophrenia. <i>Neurolmage: Clinical</i> , 2021, 32, 102813.	1.4	5
14	Response and Toxicity to the Second Course of 3 Cycles of 177Lu-PSMA Therapy Every 4 Weeks in Patients with Metastatic Castration-Resistant Prostate Cancer. <i>Cancers</i> , 2021, 13, 2489.	1.7	6
15	PSMA Expression in 122 Treatment Naive Glioma Patients Related to Tumor Metabolism in 11C-Methionine PET and Survival. <i>Journal of Personalized Medicine</i> , 2021, 11, 624.	1.1	11
16	Cross-Modality Imaging of Murine Tumor Vasculatureâ€“a Feasibility Study. <i>Molecular Imaging and Biology</i> , 2021, 23, 874-893.	1.3	7
17	Single-lesion Prostate-specific Membrane Antigen Protein Expression (PSMA) and Response to [177Lu]-PSMA-ligand Therapy in Patients with Castration-resistant Prostate Cancer. <i>European Urology Open Science</i> , 2021, 30, 63-66.	0.2	4
18	If It Works, Donâ€™t Touch It? A Cell-Based Approach to Studying 2-[18F]FDG Metabolism. <i>Pharmaceuticals</i> , 2021, 14, 910.	1.7	2

#	ARTICLE	IF	CITATIONS
19	Renal and Salivary Gland Functions after Three Cycles of PSMA-617 Therapy Every Four Weeks in Patients with Metastatic Castration-Resistant Prostate Cancer. <i>Current Oncology</i> , 2021, 28, 3692-3704.	0.9	5
20	Discovery of melanin-concentrating hormone receptor 1 in brown adipose tissue. <i>Annals of the New York Academy of Sciences</i> , 2021, 1494, 70-86.	1.8	2
21	First-in-human brain PET imaging of the GluN2B-containing N-methyl-D-aspartate receptor with (R)-11C-Me-NB1. <i>Journal of Nuclear Medicine</i> , 2021, , jnumed.121.262427.	2.8	14
22	Immune Checkpoint Inhibitor Therapy Induces Inflammatory Activity in the Large Arteries of Lymphoma Patients under 50 Years of Age. <i>Biology</i> , 2021, 10, 1206.	1.3	3
23	Advancing Biomarker Development Through Convergent Engagement: Summary Report of the 2nd International Danube Symposium on Biomarker Development, Molecular Imaging and Applied Diagnostics; March 14-16, 2018; Vienna, Austria. <i>Molecular Imaging and Biology</i> , 2020, 22, 47-65.	1.3	4
24	Brain glucose uptake during transcranial direct current stimulation measured with functional [18F]FDG-PET. <i>Brain Imaging and Behavior</i> , 2020, 14, 477-484.	1.1	5
25	Response assessment using [⁶⁸ Ga]Ga-PSMA ligand PET in patients undergoing systemic therapy for metastatic castration-resistant prostate cancer. <i>Prostate</i> , 2020, 80, 74-82.	1.2	49
26	Clinical outcome of standardized 177Lu-PSMA-617 therapy in metastatic prostate cancer patients receiving 7400 MBq every 4 weeks. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2020, 47, 713-720.	3.3	46
27	Enhanced arecoline derivatives as muscarinic acetylcholine receptor M1 ligands for potential application as PET radiotracers. <i>European Journal of Medicinal Chemistry</i> , 2020, 204, 112623.	2.6	8
28	Immune Checkpoint Inhibitor Therapy Induces Inflammatory Activity in Large Arteries. <i>Circulation</i> , 2020, 142, 2396-2398.	1.6	45
29	The relationship between cholecystokinin secretion and pancreatic [11C]methionine uptake in patients after partial pancreaticoduodenectomy. <i>Annals of Nuclear Medicine</i> , 2020, 34, 691-695.	1.2	0
30	Association of dopamine D2/3 receptor binding potential measured using PET and [11C]-(+)-PHNO with post-mortem DRD2/3 gene expression in the human brain. <i>NeuroImage</i> , 2020, 223, 117270.	2.1	11
31	Sorbitol as a Polar Pharmacological Modifier to Enhance the Hydrophilicity of 99mTc-Tricarbonyl-Based Radiopharmaceuticals. <i>Molecules</i> , 2020, 25, 2680.	1.7	2
32	Topologically Guided Prioritization of Candidate Gene Transcripts Coexpressed with the 5-HT1A Receptor by Combining In Vivo PET and Allen Human Brain Atlas Data. <i>Cerebral Cortex</i> , 2020, 30, 3771-3780.	1.6	10
33	Utility of Absolute Quantification in Non-lesional Extratemporal Lobe Epilepsy Using FDG PET/MR Imaging. <i>Frontiers in Neurology</i> , 2020, 11, 54.	1.1	21
34	On the relationship of first-episode psychosis to the amphetamine-sensitized state: a dopamine D2/3 receptor agonist radioligand study. <i>Translational Psychiatry</i> , 2020, 10, 2.	2.4	25
35	Machine learning classification of ADHD and HC by multimodal serotonergic data. <i>Translational Psychiatry</i> , 2020, 10, 104.	2.4	39
36	Inhibition of Lipid Accumulation in Skeletal Muscle and Liver Cells: A Protective Mechanism of Bilirubin Against Diabetes Mellitus Type 2. <i>Frontiers in Pharmacology</i> , 2020, 11, 636533.	1.6	5

#	ARTICLE	IF	CITATIONS
37	SNAPshots of the MCHR1: a Comparison Between the PET-Tracers [¹⁸ F]FE@SNAP and [¹¹ C]SNAP-7941. Molecular Imaging and Biology, 2019, 21, 257-268.	1.3	5
38	Prospective non-invasive evaluation of CXCR4 expression for the diagnosis of MALT lymphoma using [⁶⁸ Ga]Ga-Pentixafor-PET/MRI. Theranostics, 2019, 9, 3653-3658.	4.6	42
39	Serotonin Transporter Binding in the Human Brain After Pharmacological Challenge Measured Using PET and PET/MR. Frontiers in Molecular Neuroscience, 2019, 12, 172.	1.4	6
40	Prospective evaluation of the performance of [⁶⁸ Ga]Ga-PSMA-11 PET/CT(MRI) for lymph node staging in patients undergoing superextended salvage lymph node dissection after radical prostatectomy. European Journal of Nuclear Medicine and Molecular Imaging, 2019, 46, 2169-2177.	3.3	30
41	In vitro Radiopharmaceutical Evidence for MCHR1 Binding Sites in Murine Brown Adipocytes. Frontiers in Endocrinology, 2019, 10, 324.	1.5	6
42	Synthesis and in vitro evaluation of new translocator protein ligands designed for positron emission tomography. Future Medicinal Chemistry, 2019, 11, 539-550.	1.1	3
43	Toward the Optimization of (+)-[¹¹ C]PHNO Synthesis: Time Reduction and Process Validation. Contrast Media and Molecular Imaging, 2019, 2019, 1-13.	0.4	1
44	Sex-differences in [⁶⁸ Ga]Ga-DOTANOC biodistribution. Nuclear Medicine and Biology, 2019, 76-77, 15-20.	0.3	4
45	Epistasis of HTR1A and BDNF risk genes alters cortical 5-HT1A receptor binding: PET results link genotype to molecular phenotype in depression. Translational Psychiatry, 2019, 9, 5.	2.4	7
46	Binding Affinity of Some Endogenous and Synthetic TSPO Ligands Regarding the rs6971 Polymorphism. International Journal of Molecular Sciences, 2019, 20, 563.	1.8	13
47	Multimodal [¹⁸ F]FDG PET/CT Is a Direct Readout for Inflammatory Bone Repair: A Longitudinal Study in TNF α Transgenic Mice. Journal of Bone and Mineral Research, 2019, 34, 1632-1645.	3.1	8
48	Modeling the acute pharmacological response to selective serotonin reuptake inhibitors in human brain using simultaneous PET/MR imaging. European Neuropsychopharmacology, 2019, 29, 711-719.	0.3	11
49	(R)-[¹⁸ F]NEBIFQUINIDE: A promising new PET tracer for TSPO imaging. European Journal of Medicinal Chemistry, 2019, 176, 410-418.	2.6	14
50	Technical Aspect of the Automated Synthesis and Real-Time Kinetic Evaluation of [¹¹ C]SNAP-7941. Journal of Visualized Experiments, 2019, , .	0.2	2
51	Characterization of pharmacological response to selective serotonin reuptake inhibitors using clustering of resting-state hybrid PET/MR data. European Neuropsychopharmacology, 2019, 29, S603-S604.	0.3	0
52	Characterization of Bone Lesions in Myeloma Before and During Anticancer Therapy Using [¹⁸ F]F-FDG-PET/CT and [¹⁸ F]F-NaF-PET/CT. Anticancer Research, 2019, 39, 1943-1952.	0.5	3
53	Attenuation Correction Approaches for Serotonin Transporter Quantification With PET/MRI. Frontiers in Physiology, 2019, 10, 1422.	1.3	5
54	Response assessment using ⁶⁸ Ga-PSMA ligand PET in patients undergoing ¹⁷⁷ Lu-PSMA radioligand therapy for metastatic castration-resistant prostate cancer. European Journal of Nuclear Medicine and Molecular Imaging, 2019, 46, 1063-1072.	3.3	100

#	ARTICLE	IF	CITATIONS
55	The effect of electroconvulsive therapy on cerebral monoamine oxidase A expression in treatment-resistant depression investigated using positron emission tomography. Brain Stimulation, 2019, 12, 714-723.	0.7	24
56	Optimization of the Automated Synthesis of [¹¹ C]mHED Administered and Apparent Molar Activities. Pharmaceuticals, 2019, 12, 12.	1.7	1
57	Parcellation of the Human Cerebral Cortex Based on Molecular Targets in the Serotonin System Quantified by Positron Emission Tomography In vivo. Cerebral Cortex, 2019, 29, 372-382.	1.6	12
58	Explorative analysis of retrospective data of patients with esophageal cancer at the Department of Nuclear Medicine at the Medical University of Vienna: Predicting 30-month survival and progress-free survival using Supervised Machine Learning. Nuklearmedizin - NuclearMedicine, 2019, 58, .	0.3	0
59	Task-relevant brain networks identified with simultaneous PET/MR imaging of metabolism and connectivity. Brain Structure and Function, 2018, 223, 1369-1378.	1.2	34
60	[¹⁸ F]FEPPA: Improved Automated Radiosynthesis, Binding Affinity, and Preliminary in Vitro Evaluation in Colorectal Cancer. ACS Medicinal Chemistry Letters, 2018, 9, 177-181.	1.3	15
61	A new method measuring the interaction of radiotracers with the human P-glycoprotein (P-gp) transporter. Nuclear Medicine and Biology, 2018, 60, 29-36.	0.3	5
62	[¹¹ C]acetate PET as a tool for diagnosis of liver steatosis. Abdominal Radiology, 2018, 43, 2963-2969.	1.0	3
63	Assessment of Ketamine Binding of the Serotonin Transporter in Humans with Positron Emission Tomography. International Journal of Neuropsychopharmacology, 2018, 21, 145-153.	1.0	22
64	Probing the association between serotonin-1A autoreceptor binding and amygdala reactivity in healthy volunteers. NeuroImage, 2018, 171, 1-5.	2.1	6
65	Spatial analysis and high resolution mapping of the human whole-brain transcriptome for integrative analysis in neuroimaging. NeuroImage, 2018, 176, 259-267.	2.1	87
66	Microfluidic ⁶⁸ Ga-labeling: a proof of principle study. Dalton Transactions, 2018, 47, 5997-6004.	1.6	9
67	Changes in Tumor Biology During Chemoradiation of Cervix Cancer Assessed by Multiparametric MRI and Hypoxia PET. Molecular Imaging and Biology, 2018, 20, 160-169.	1.3	16
68	Visual and semiquantitative ¹¹ C-methionine PET: an independent prognostic factor for survival of newly diagnosed and treatment-naïve gliomas. Neuro-Oncology, 2018, 20, 411-419.	0.6	22
69	[⁶⁸ Ga]Pentixafor-PET/MRI for the detection of Chemokine receptor 4 expression in atherosclerotic plaques. European Journal of Nuclear Medicine and Molecular Imaging, 2018, 45, 558-566.	3.3	60
70	Glioma Survival Prediction with Combined Analysis of In Vivo ¹¹ C-MET PET Features, Ex Vivo Features, and Patient Features by Supervised Machine Learning. Journal of Nuclear Medicine, 2018, 59, 892-899.	2.8	94
71	Expanding LogP: Present possibilities. Nuclear Medicine and Biology, 2018, 58, 20-32.	0.3	17
72	EANM guideline for radionuclide therapy with radium-223 of metastatic castration-resistant prostate cancer. European Journal of Nuclear Medicine and Molecular Imaging, 2018, 45, 824-845.	3.3	108

#	ARTICLE	IF	CITATIONS
73	Development and evaluation of a rapid analysis for HEPES determination in ⁶⁸ Ga-radiotracers. EJNMMI Research, 2018, 8, 95.	1.1	8
74	Comparison of fully-automated radiosyntheses of [¹¹ C]erlotinib for preclinical and clinical use starting from in target produced [¹¹ C]CO ₂ or [¹¹ C]CH ₄ . EJNMMI Radiopharmacy and Chemistry, 2018, 3, 8.	1.8	10
75	Brain monoamine oxidase A in seasonal affective disorder and treatment with bright light therapy. Translational Psychiatry, 2018, 8, 198.	2.4	22
76	EGFR is required for FOS-dependent bone tumor development via RSK2/CREB signaling. EMBO Molecular Medicine, 2018, 10, .	3.3	24
77	Molar activity – The keystone in ¹¹ C-radiochemistry: An explorative study using the gas phase method. Nuclear Medicine and Biology, 2018, 67, 21-26.	0.3	4
78	L-[S-methyl- ¹¹ C]methionine – An example of radiosynthetic optimization. Applied Radiation and Isotopes, 2018, 141, 107-111.	0.7	3
79	Reduced task durations in functional PET imaging with [¹⁸ F]FDG approaching that of functional MRI. NeuroImage, 2018, 181, 323-330.	2.1	59
80	Preclinical In Vitro and In Vivo Evaluation of [¹⁸ F]FE@SUPPLY for Cancer PET Imaging: Limitations of a Xenograft Model for Colorectal Cancer. Contrast Media and Molecular Imaging, 2018, 2018, 1-9.	0.4	5
81	An Overview of PET Radiochemistry, Part 1: The Covalent Labels ¹⁸ F, ¹¹ C, and ¹³ N. Journal of Nuclear Medicine, 2018, 59, 1350-1354.	2.8	26
82	PSMA Ligand PET/MRI for Primary Prostate Cancer: Staging Performance and Clinical Impact. Clinical Cancer Research, 2018, 24, 6300-6307.	3.2	112
83	Speed matters to raise molar radioactivity: Fast HPLC shortens the quality control of C-11 PET-tracers. Nuclear Medicine and Biology, 2018, 57, 28-33.	0.3	12
84	**Postprandial pancreatic [¹¹ C]methionine uptake after pancreaticoduodenectomy mirrors basal beta cell function and insulin release. European Journal of Nuclear Medicine and Molecular Imaging, 2017, 44, 509-516.	3.3	3
85	Simple and rapid quantification of serotonin transporter binding using [¹¹ C]DASB bolus plus constant infusion. NeuroImage, 2017, 149, 23-32.	2.1	19
86	New approaches for the reliable in vitro assessment of binding affinity based on high-resolution real-time data acquisition of radioligand-receptor binding kinetics. EJNMMI Research, 2017, 7, 22.	1.1	24
87	Association Between Osteogenesis and Inflammation During the Progression of Calcified Plaque Evaluated by ¹⁸ F-Fluoride and ¹⁸ F-FDG. Journal of Nuclear Medicine, 2017, 58, 968-974.	2.8	40
88	Association of Protein Distribution and Gene Expression Revealed by PET and Post-Mortem Quantification in the Serotonergic System of the Human Brain. Cerebral Cortex, 2017, 27, 117-130.	1.6	30
89	The influence of the rs6295 gene polymorphism on serotonin-1A receptor distribution investigated with PET in patients with major depression applying machine learning. Translational Psychiatry, 2017, 7, e1150-e1150.	2.4	22
90	Log P , a yesterday's value?. Nuclear Medicine and Biology, 2017, 50, 1-10.	0.3	62

#	ARTICLE	IF	CITATIONS
91	In vivo evaluation of radiotracers targeting the melanin-concentrating hormone receptor 1: [11C]SNAP-7941 and [18F]FE@SNAP reveal specific uptake in the ventricular system. Scientific Reports, 2017, 7, 8054.	1.6	6
92	Reconsider logP!. Nuclear Medicine and Biology, 2017, 54, 42.	0.3	3
93	In vivo magnetic resonance imaging of pancreatic tumors using iron oxide nanoworms targeted with PTR86 peptide. Colloids and Surfaces B: Biointerfaces, 2017, 158, 423-430.	2.5	11
94	Impact of hybrid PET/MR technology on multiparametric imaging and treatment response assessment of cervix cancer. Radiotherapy and Oncology, 2017, 125, 420-425.	0.3	25
95	The value of [11C]-acetate PET and [18F]-FDG PET in hepatocellular carcinoma before and after treatment with transarterial chemoembolization and bevacizumab. European Journal of Nuclear Medicine and Molecular Imaging, 2017, 44, 1732-1741.	3.3	20
96	Altered interregional molecular associations of the serotonin transporter in attention deficit/hyperactivity disorder assessed with PET. Human Brain Mapping, 2017, 38, 792-802.	1.9	21
97	Monoamine oxidase A distribution volume as a correlate for electroconvulsive therapy “ preliminary results. European Neuropsychopharmacology, 2017, 27, S708-S709.	0.3	1
98	Influence of serotonergic gene variants on serotonin transporter binding in ADHD. European Neuropsychopharmacology, 2017, 27, S707.	0.3	0
99	Investigating dose dependency of ketamine binding on the serotonin transporter with positron emission tomography. European Neuropsychopharmacology, 2017, 27, S779.	0.3	0
100	Effects of Selective Serotonin Reuptake Inhibitors on Interregional Relation of Serotonin Transporter Availability in Major Depression. Frontiers in Human Neuroscience, 2017, 11, 48.	1.0	50
101	Multiparametric [11C]Acetate positron emission tomography-magnetic resonance imaging in the assessment and staging of prostate cancer. PLoS ONE, 2017, 12, e0180790.	1.1	7
102	Development of a radiolabeled caninized anti-EGFR antibody for comparative oncology trials. Oncotarget, 2017, 8, 83128-83141.	0.8	7
103	Multiparametric [18F]Fluorodeoxyglucose/ [18F]Fluoromisonidazole Positron Emission Tomography/ Magnetic Resonance Imaging of Locally Advanced Cervical Cancer for the Non-Invasive Detection of Tumor Heterogeneity: A Pilot Study. PLoS ONE, 2016, 11, e0155333.	1.1	45
104	PM478. Imaging the effects of d-amphetamine in the human brain for modelling dopaminergic alterations in schizophrenia. International Journal of Neuropsychopharmacology, 2016, 19, 74-74.	1.0	1
105	PS168. Hybrid PET/MR imaging of serotonin transporter occupancy and brain activation to elucidate the mechanism of action of selective serotonin reuptake inhibitors. International Journal of Neuropsychopharmacology, 2016, 19, 60-61.	1.0	0
106	Quantification of Task-Specific Glucose Metabolism with Constant Infusion of ¹⁸ F-FDG. Journal of Nuclear Medicine, 2016, 57, 1933-1940.	2.8	64
107	Attenuation of habenula “default mode network connectivity by selective serotonin reuptake inhibitors, a pharmacological hybrid PET/MR study. European Neuropsychopharmacology, 2016, 26, S317.	0.3	1
108	Neurochemical and behavioral sensitization to d-amphetamine in healthy subjects measured with [¹¹ C]-(+)-PHNO-PET. European Psychiatry, 2016, 33, S105-S106.	0.1	0

#	ARTICLE	IF	CITATIONS
109	[18F]FMeNER-D2: A systematic in vitro analysis of radio-metabolism. Nuclear Medicine and Biology, 2016, 43, 490-495.	0.3	6
110	[18F]FE@SNAPâ€”a specific PET tracer for melanin-concentrating hormone receptor 1 imaging?. EJNMMI Research, 2016, 6, 31.	1.1	8
111	Effects of norepinephrine transporter gene variants on <scp>NET</scp> binding in <scp>ADHD</scp> and healthy controls investigated by <scp>PET</scp>. Human Brain Mapping, 2016, 37, 884-895.	1.9	37
112	Development of a Novel Nonpeptidic ¹⁸F-Labeled Radiotracer for in Vivo Imaging of Oxytocin Receptors with Positron Emission Tomography. Journal of Medicinal Chemistry, 2016, 59, 1800-1817.	2.9	17
113	Clinical Value of 18F-fluorodihydroxyphenylalanine Positron Emission Tomography/Contrast-enhanced Computed Tomography (18F-DOPA PET/CT) in Patients with Suspected Paraganglioma. Anticancer Research, 2016, 36, 4187-93.	0.5	3
114	P.1.i.047 Interregional changes in serotonin transporter availability upon treatment with selective serotonin reuptake inhibitors. European Neuropsychopharmacology, 2015, 25, S327-S328.	0.3	0
115	Radiosynthesis and first preclinical evaluation of the novel norepinephrine transporter pet-ligand [11C]ME@HAPTHI. EJNMMI Research, 2015, 5, 113.	1.1	11
116	Evaluation of fatty acid synthase in prostate cancer recurrence: SUV of [¹¹ C]acetate PET as a prognostic marker. Prostate, 2015, 75, 1760-1767.	1.2	28
117	2-Fluoro-N-methyl-N-({(3S,4S)-4-[2-(trifluoromethyl)phenoxy]-3,4-dihydro-1H-isochromen-3-yl}methyl)ethanamine. MolBank, 2015, 2015, M858.	0.2	0
118	1-(3-Amino-1-phenylpropyl)-3-(2-fluorophenyl)-1,3-dihydro-2H-benzimidazol-2-one. MolBank, 2015, 2015, M867.	0.2	0
119	Synthesis and in Silico Evaluation of Novel Compounds for PET-Based Investigations of the Norepinephrine Transporter. Molecules, 2015, 20, 1712-1730.	1.7	6
120	2-Fluoro-N-methyl-N-{{[(3S*,4S*)-4-(2-methylphenoxy)-3,4-dihydro-1H-isochromen-3-yl]methyl}ethanamine. MolBank, 2015, 2015, M862.	0.2	0
121	Parameter evaluation and fully-automated radiosynthesis of [11 C]harmin for imaging of MAO-A for clinical trials. Applied Radiation and Isotopes, 2015, 97, 182-187.	0.7	16
122	[18F]FE@SUPPY: a suitable PET tracer for the adenosine A3 receptor? An in vivo study in rodents. European Journal of Nuclear Medicine and Molecular Imaging, 2015, 42, 741-749.	3.3	5
123	High-Dose Testosterone Treatment Increases Serotonin Transporter Binding in Transgender People. Biological Psychiatry, 2015, 78, 525-533.	0.7	75
124	Interaction between 5-HTTLPR and 5-HT1B genotype status enhances cerebral 5-HT1A receptor binding. Neurolmage, 2015, 111, 505-512.	2.1	12
125	Hide and seek: a comparative autoradiographic in vitro investigation of the adenosine A3 receptor. European Journal of Nuclear Medicine and Molecular Imaging, 2015, 42, 928-939.	3.3	17
126	Effects of Silexan on the Serotonin-1A Receptor and Microstructure of the Human Brain: A Randomized, Placebo-Controlled, Double-Blind, Cross-Over Study with Molecular and Structural Neuroimaging. International Journal of Neuropsychopharmacology, 2015, 18, pyu063-pyu063.	1.0	49

#	ARTICLE	IF	CITATIONS
127	P.1.i.037 Effects of norepinephrine transporter gene variants on protein binding in patients with ADHD using PET. European Neuropsychopharmacology, 2015, 25, S321-S322.	0.3	0
128	Detection of Bone Metastases Using ¹¹ C-Acetate PET in Patients with Prostate Cancer with Biochemical Recurrence. Anticancer Research, 2015, 35, 6787-91.	0.5	15
129	A One-Step Microwave-Assisted Synthetic Method for an O/S-Chemoselective Route to Derivatives of the First Adenosine A3 PET Radiotracer. Molecules, 2014, 19, 4076-4082.	1.7	0
130	¹¹ C-Methionine PET/CT Imaging of ^{99m} Tc-MIBI-SPECT/CT-Negative Patients With Primary Hyperparathyroidism and Previous Neck Surgery. Journal of Clinical Endocrinology and Metabolism, 2014, 99, 4199-4205.	1.8	32
131	Attenuated serotonin transporter association between dorsal raphe and ventral striatum in major depression. Human Brain Mapping, 2014, 35, 3857-3866.	1.9	50
132	The Norepinephrine Transporter in Attention-Deficit/Hyperactivity Disorder Investigated With Positron Emission Tomography. JAMA Psychiatry, 2014, 71, 1340.	6.0	44
133	Imaging Biomarkers or Biomarker Imaging?. Pharmaceuticals, 2014, 7, 765-778.	1.7	13
134	Effects of hormone replacement therapy on cerebral serotonin-1A receptor binding in postmenopausal women examined with [carbonyl- ¹¹ C]WAY-100635. Psychoneuroendocrinology, 2014, 45, 1-10.	1.3	23
135	Relation of progesterone and DHEAS serum levels to 5-HT1A receptor binding potential in pre- and postmenopausal women. Psychoneuroendocrinology, 2014, 46, 52-63.	1.3	19
136	Impact of COMT genotype on serotonin-1A receptor binding investigated with PET. Brain Structure and Function, 2014, 219, 2017-2028.	1.2	13
137	Cerebral serotonin transporter asymmetry in females, males and male-to-female transsexuals measured by PET in vivo. Brain Structure and Function, 2014, 219, 171-183.	1.2	28
138	In vivo P-glycoprotein function before and after epilepsy surgery. Neurology, 2014, 83, 1326-1331.	1.5	37
139	Development of potential selective and reversible pyrazoline based MAO-B inhibitors as MAO-B PET tracer precursors and reference substances for the early detection of Alzheimer's disease. Bioorganic and Medicinal Chemistry Letters, 2014, 24, 4490-4495.	1.0	9
140	Regional differences in SERT occupancy after acute and prolonged SSRI intake investigated by brain PET. NeuroImage, 2014, 88, 252-262.	2.1	54
141	Pioglitazone decreases portosystemic shunting by modulating inflammation and angiogenesis in cirrhotic and non-cirrhotic portal hypertensive rats. Journal of Hepatology, 2014, 60, 1135-1142.	1.8	39
142	Comparative autoradiographic in vitro investigation of melanin concentrating hormone receptor 1 ligands in the central nervous system. European Journal of Pharmacology, 2014, 735, 177-183.	1.7	10
143	Exploring the Impact of BDNF Val66Met Genotype on Serotonin Transporter and Serotonin-1A Receptor Binding. PLoS ONE, 2014, 9, e106810.	1.1	11
144	Gadoxetate-enhanced versus diffusion-weighted MRI for fused Ga-68-DOTANOC PET/MRI in patients with neuroendocrine tumours of the upper abdomen. European Radiology, 2013, 23, 1978-1985.	2.3	41

#	ARTICLE	IF	CITATIONS
145	Nebivolol treatment increases splanchnic blood flow and portal pressure in cirrhotic rats via modulation of nitric oxide signalling. <i>Liver International</i> , 2013, 33, 561-568.	1.9	16
146	Preclinical in vitro & in vivo evaluation of [11C]SNAP-7941 – the first PET tracer for the melanin concentrating hormone receptor 1. <i>Nuclear Medicine and Biology</i> , 2013, 40, 919-925.	0.3	20
147	P.2.b.044 Serotonin transporter association between dorsal raphe and ventral striatum is diminished in major depression. <i>European Neuropsychopharmacology</i> , 2013, 23, S345.	0.3	0
148	Synthesis, radiosynthesis and first in vitro evaluation of novel PET-tracers for the dopamine transporter: [11C]IPCIT and [18F]FE@IPCIT. <i>Bioorganic and Medicinal Chemistry</i> , 2013, 21, 7562-7569.	1.4	8
149	Impact of electroconvulsive therapy on 5-HT1A receptor binding in major depression. <i>Molecular Psychiatry</i> , 2013, 18, 1-1.	4.1	10
150	Reliable set-up for in-loop 11C-carboxylations using Grignard reactions for the preparation of [carbonyl-11C]WAY-100635 and [11C]-(+)-PHNO. <i>Applied Radiation and Isotopes</i> , 2013, 82, 75-80.	0.7	20
151	[18F]FMeNER-D2: Reliable fully-automated synthesis for visualization of the norepinephrine transporter. <i>Nuclear Medicine and Biology</i> , 2013, 40, 1049-1054.	0.3	17
152	Application of image-derived and venous input functions in major depression using [carbonyl-11C]WAY-100635. <i>Nuclear Medicine and Biology</i> , 2013, 40, 371-377.	0.3	62
153	Development and automation of a novel NET-PET tracer: [11C]Me@APPI. <i>Nuclear Medicine and Biology</i> , 2013, 40, 295-303.	0.3	11
154	Interaction of ¹¹ C-Tariquidar and ¹¹ C-Elacridar with P-Glycoprotein and Breast Cancer Resistance Protein at the Human Blood–Brain Barrier. <i>Journal of Nuclear Medicine</i> , 2013, 54, 1181-1187.	2.8	45
155	Preparation and First Preclinical Evaluation of [18F]FE@SNAP: A Potential PET Tracer for the Melanin Concentrating Hormone Receptor 1 (MCHR1). <i>Scientia Pharmaceutica</i> , 2013, 81, 625-639.	0.7	14
156	Global decrease of serotonin-1A receptor binding after electroconvulsive therapy in major depression measured by PET. <i>Molecular Psychiatry</i> , 2013, 18, 93-100.	4.1	98
157	Syntheses of Precursors and Reference Compounds of the Melanin-Concentrating Hormone Receptor 1 (MCHR1) Tracers [11C]SNAP-7941 and [18F]FE@SNAP for Positron Emission Tomography. <i>Molecules</i> , 2013, 18, 12119-12143.	1.7	5
158	Differential modulation of the default mode network via serotonin-1A receptors. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2012, 109, 2619-2624.	3.3	109
159	Quantification of the radio-metabolites of the serotonin-1A receptor radioligand [carbonyl-11C]WAY-100635 in human plasma: An HPLC-assay which enables measurement of two patients in parallel. <i>Applied Radiation and Isotopes</i> , 2012, 70, 2730-2736.	0.7	3
160	P.4.002 Serotonin transporter ratio between raphe nuclei and projection areas predicts SSRI treatment response in major depression. <i>European Neuropsychopharmacology</i> , 2012, 22, S85.	0.3	0
161	Light-dependent alteration of serotonin-1A receptor binding in cortical and subcortical limbic regions in the human brain. <i>World Journal of Biological Psychiatry</i> , 2012, 13, 413-422.	1.3	57
162	Radiosynthesis of [11C]SNAP-7941 – the first PET-tracer for the melanin concentrating hormone receptor 1 (MCHR1). <i>Applied Radiation and Isotopes</i> , 2012, 70, 2287-2294.	0.7	15

#	ARTICLE	IF	CITATIONS
163	Optimization of [¹¹ C]DASB-synthesis: Vessel-based and flow-through microreactor methods. Applied Radiation and Isotopes, 2012, 70, 2615-2620.	0.7	14
164	[¹⁸ F]FE@SNAP A new PET tracer for the melanin concentrating hormone receptor 1 (MCHR1): Microfluidic and vessel-based approaches. Bioorganic and Medicinal Chemistry, 2012, 20, 5936-5940.	1.4	28
165	Combining image-derived and venous input functions enables quantification of serotonin-1A receptors with [carbonyl- ¹¹ C]WAY-100635 independent of arterial sampling. NeuroImage, 2012, 62, 199-206.	2.1	19
166	Normative database of the serotonergic system in healthy subjects using multi-tracer PET. NeuroImage, 2012, 63, 447-459.	2.1	126
167	Prediction of SSRI treatment response in major depression based on serotonin transporter interplay between median raphe nucleus and projection areas. NeuroImage, 2012, 63, 874-881.	2.1	124
168	Serotonin-1A receptor binding is positively associated with gray matter volume A multimodal neuroimaging study combining PET and structural MRI. NeuroImage, 2012, 63, 1091-1098.	2.1	27
169	Radiolabeling of [¹⁸ F]altanserine a microfluidic approach. Nuclear Medicine and Biology, 2012, 39, 1087-1092.	0.3	25
170	Pgp-Mediated Interaction Between (R)-[¹¹ C]Verapamil and Tariquidar at the Human Blood-Brain Barrier: A Comparison With Rat Data. Clinical Pharmacology and Therapeutics, 2012, 91, 227-233.	2.3	108
171	FC10-05 - Attenuated serotonin transporter association between midbrain and nucleus accumbens in major depression. European Psychiatry, 2011, 26, 1868-1868.	0.1	0
172	Multimodal imaging of an astrocytoma affecting the amygdalar region. European Psychiatry, 2011, 26, 924-924.	0.1	0
173	Cortisol plasma levels are associated with serotonin - 1A receptor binding in postmenopausal women. European Psychiatry, 2011, 26, 933-933.	0.1	0
174	The stability of methyl-, ethyl- and fluoroethylesters against carboxylesterases in vitro: there is no difference. Nuclear Medicine and Biology, 2011, 38, 13-17.	0.3	6
175	Microfluidic preparation of [¹⁸ F]FE@SUPPLY and [¹⁸ F]FE@SUPPLY:2 comparison with conventional radiosyntheses. Nuclear Medicine and Biology, 2011, 38, 427-434.	0.3	25
176	Radiopharmaceutical considerations on bone seeker uptake: should we learn from therapeutical targets of bisphosphonates?. Nuclear Medicine and Biology, 2011, 38, 617-618.	0.3	2
177	Optimization of the radiosynthesis of the Alzheimer tracer 2-(4-N-[¹¹ C]methylaminophenyl)-6-hydroxybenzothiazole ([¹¹ C]PIB). Applied Radiation and Isotopes, 2011, 69, 1212-1217.	0.7	26
178	Progesterone Level Predicts Serotonin-1A Receptor Binding in the Male Human Brain. Neuroendocrinology, 2011, 94, 84-88.	1.2	18
179	Cortisol plasma levels in social anxiety disorder patients correlate with serotonin-1A receptor binding in limbic brain regions. International Journal of Neuropsychopharmacology, 2010, 13, 1129-1143.	1.0	54
180	Label and go A fast and easy radiolabelling method for pellets. Applied Radiation and Isotopes, 2010, 68, 399-403.	0.7	0

#	ARTICLE	IF	CITATIONS
181	The "Drill & Fill" Method. Scientia Pharmaceutica, 2010, 78, 650-650.	0.7	0
182	Escitalopram Enhances the Association of Serotonin-1A Autoreceptors to Heteroreceptors in Anxiety Disorders. Journal of Neuroscience, 2010, 30, 14482-14489.	1.7	52
183	Segmentation of [11C]DASB and [carbonyl-11C]WAY-100635 PET brain images using linear discriminant analysis. NeuroImage, 2010, 52, S155-S156.	2.1	1
184	Hypothalamic serotonin-1A receptor binding measured by PET predicts the plasma level of dehydroepiandrosterone sulfate in healthy women. Neuroscience Letters, 2010, 476, 161-165.	1.0	15
185	Basics and principles of radiopharmaceuticals for PET/CT. European Journal of Radiology, 2010, 73, 461-469.	1.2	104
186	[18F]FE@SUPPY and [18F]FE@SUPPY:2 " metabolic considerations. Nuclear Medicine and Biology, 2010, 37, 421-426.	0.3	15
187	Central serotonin 1A receptor binding in temporal lobe epilepsy: A [carbonyl-11C]WAY-100635 PET study. Epilepsy and Behavior, 2010, 19, 467-473.	0.9	37
188	Radiosynthesis of a novel potential adenosine A3 receptor ligand, 5-ethyl 2,4-diethyl-3-((2-[18F]fluoroethyl)sulfanylcarbonyl)-6-phenylpyridine-5-carboxylate ([18F]FE@SUPPY:2). Radiochimica Acta, 2009, 97, 753-758.	0.5	5
189	Aggression is related to frontal serotonininâ€1A receptor distribution as revealed by PET in healthy subjects. Human Brain Mapping, 2009, 30, 2558-2570.	1.9	84
190	Influence of escitalopram treatment on 5-HT1A receptor binding in limbic regions in patients with anxiety disorders. Molecular Psychiatry, 2009, 14, 1040-1050.	4.1	87
191	Simple and rapid preparation of [11C]DASB with high quality and reliability for routine applications. Applied Radiation and Isotopes, 2009, 67, 1654-1660.	0.7	27
192	Sorafenib attenuates the portal hypertensive syndrome in partial portal vein ligated rats. Journal of Hepatology, 2009, 51, 865-873.	1.8	95
193	Lateralization of the serotonin-1A receptor distribution in language areas revealed by PET. NeuroImage, 2009, 45, 598-605.	2.1	72
194	Automatisation and First Evaluation of [18F]FE@SUPPY:2, an Alternative PET-Tracer for the Adenosine A3 Receptor: A Comparison with [18F]FE@SUPPY. The Open Nuclear Medicine Journal, 2009, 1, 15-23.	0.2	8
195	Adrenal Carcinoma " Radionuclide Imaging. , 2009, , 29-42.		0
196	The serotonin-1A receptor distribution in healthy men and women measured by PET and [carbonyl-11C]WAY-100635. European Journal of Nuclear Medicine and Molecular Imaging, 2008, 35, 2159-2168.	3.3	59
197	Preparation and first evaluation of [18F]FE@SUPPY: a new PET tracer for the adenosine A3 receptor. Nuclear Medicine and Biology, 2008, 35, 61-66.	0.3	28
198	Metabolism and autoradiographic evaluation of [18F]FE@CIT: a Comparison with [123I]Î²2-CIT and [123I]FP-CIT. Nuclear Medicine and Biology, 2008, 35, 475-479.	0.3	5

#	ARTICLE	IF	CITATIONS
199	What to consider in the development of new bone seekers: mechanistic and tracer-related aspects. Nuclear Medicine and Biology, 2008, 35, 817-824.	0.3	8
200	Preparation and pre-vivo evaluation of no-carrier-added, carrier-added and cross-complexed [68Ga]-EDTMP formulations. European Journal of Pharmaceutics and Biopharmaceutics, 2008, 68, 406-412.	2.0	27
201	S.07.04 Progesterone and estradiol plasma levels modulate serotonin-1A binding in the human brain. European Neuropsychopharmacology, 2008, 18, S168.	0.3	0
202	Multimodal imaging of human early visual cortex by combining functional and molecular measurements with fMRI and PET. NeuroImage, 2008, 41, 204-211.	2.1	32
203	244 ANGIOGENESIS IN PORTAL HYPERTENSIVE NAD(P)HOXIDASE-KNOCKOUT-MICE IS MEDIATED BY A DIFFERENT PATHWAY THAN IN WILDTYPE ANIMALS. Journal of Hepatology, 2008, 48, S99.	1.8	1
204	Synthesis of in vivo Metabolites of the New Adenosine A3 Receptor PET-Radiotracer [18F]FE@SUPPLY. Heterocycles, 2008, 75, 339.	0.4	8
205	Radiosynthesis of the adenosine A3 receptor ligand 5-(2-[18F]fluoroethyl) 2,4-diethyl-3-(ethylsulfanylcarbonyl)- 6-phenylpyridine-5-carboxylate ([18F]FE@SUPPLY). Radiochimica Acta, 2008, 96, .	0.5	7
206	An in vitro model for the comparative evaluation of bone seeking pharmaceuticals. ALTEX: Alternatives To Animal Experimentation, 2008, 25, 51-55.	0.9	6
207	Simple and fully automated preparation of [carbonyl-11C]WAY-100635. Radiochimica Acta, 2007, 95, .	0.5	28
208	Pre vivo, ex vivo and in vivo evaluations of [68Ga]-EDTMP. Nuclear Medicine and Biology, 2007, 34, 391-397.	0.3	37
209	Evaluation of novel tropane analogues. Nuclear Medicine and Biology, 2007, 34, 591-592.	0.3	0
210	18F fluoroethylations: different strategies for the rapid translation of 11C-methylated radiotracers. Nuclear Medicine and Biology, 2007, 34, 1019-1028.	0.3	20
211	Preparation and radiosynthesis of [18F]FE@CFN (2-[18F]fluoroethyl) Tj ETQq1 1 0.784314 rgBT /Overlock 10 Tf 50 267 Td (4-[N-(1-oxo-2-oxo-1,2-dihydro-3H-imidazo[4,5-b]pyridin-3-yl)ethyl]benzamide) receptor imaging agent. Radiochimica Acta, 2007, 95, .	0.5	3
212	Reduced Serotonin-1A Receptor Binding in Social Anxiety Disorder. Biological Psychiatry, 2007, 61, 1081-1089.	0.7	276
213	In vitro evaluation of no carrier added, carrier added and cross-complexed [90Y]-EDTMP provides evidence for a novel "foreign carrier theory". Nuclear Medicine and Biology, 2006, 33, 95-99.	0.3	9
214	NCA nucleophilic radiofluorination on substituted benzaldehydes for the preparation of [18F]fluorinated aromatic amino acids. Applied Radiation and Isotopes, 2006, 64, 355-359.	0.7	5
215	Uptake of bone-seekers is solely associated with mineralisation! A study with 99mTc-MDP, 153Sm-EDTMP and 18F-fluoride on osteoblasts. European Journal of Nuclear Medicine and Molecular Imaging, 2006, 33, 491-494.	3.3	74
216	[18F]FETO for adrenocortical PET imaging: a pilot study in healthy volunteers. European Journal of Nuclear Medicine and Molecular Imaging, 2006, 33, 669-672.	3.3	33

#	ARTICLE	IF	CITATIONS
217	Imaging of adrenocortical metastases with [11C]metomidate. European Journal of Nuclear Medicine and Molecular Imaging, 2006, 33, 974-974.	3.3	11
218	[18F]FETO: metabolic considerations. European Journal of Nuclear Medicine and Molecular Imaging, 2006, 33, 928-931.	3.3	19
219	11C-Acetate Positron Emission Tomography Imaging and Image Fusion With Computed Tomography and Magnetic Resonance Imaging in Patients With Recurrent Prostate Cancer. Journal of Clinical Oncology, 2006, 24, 2513-2519.	0.8	114
220	New aspects on the preparation of [11C]Methionine—a simple and fast online approach without preparative HPLC. Applied Radiation and Isotopes, 2005, 62, 441-445.	0.7	38
221	In vitro and in vivo evaluation of [18F]ciprofloxacin for the imaging of bacterial infections with PET. European Journal of Nuclear Medicine and Molecular Imaging, 2005, 32, 143-150.	3.3	77
222	Synthesis and biodistribution of [18F]FE@CIT, a new potential tracer for the dopamine transporter. Synapse, 2005, 55, 73-79.	0.6	16
223	Binding studies of [18F]-fluoride and polyphosphonates radiolabelled with [99mTc], [111In], [153Sm] and [188Re] on bone compartments: Verification of the pre vivo model?. Bone, 2005, 37, 404-412.	1.4	20
224	[18F]Ciprofloxacin, a New Positron Emission Tomography Tracer for Noninvasive Assessment of the Tissue Distribution and Pharmacokinetics of Ciprofloxacin in Humans. Antimicrobial Agents and Chemotherapy, 2004, 48, 3850-3857.	1.4	54
225	Positron emission tomography imaging of adrenal masses: 18F-fluorodeoxyglucose and the 11 β -hydroxylase tracer 11C-metomidate. European Journal of Nuclear Medicine and Molecular Imaging, 2004, 31, 1224-30.	3.3	93
226	Labelling of EDTMP (Multibone®) with [111In], [99mTc] and [188Re] using different carriers for α -cross complexation. Applied Radiation and Isotopes, 2004, 60, 653-658.	0.7	11
227	New aspects on the preparation of [11C]acetate—a simple and fast approach via distillation. Applied Radiation and Isotopes, 2004, 61, 1147-1150.	0.7	19
228	Binding studies of [18F]-fluoride and polyphosphonates radiolabelled with [111In], [99mTc], [153Sm], and [188Re] on bone compartments: a new model for the pre vivo evaluation of bone seekers?. Bone, 2004, 34, 835-844.	1.4	16
229	Biological evaluation of $^{2-}$ [18F]fluoroflumazenil ([18F]FFMZ), a potential GABA receptor ligand for PET. Nuclear Medicine and Biology, 2004, 31, 291-295.	0.3	43
230	Bone lesion detection with carrier-added 99mTc-EDTMP in comparison with 99mTc-DPD. Nuclear Medicine Communications, 2004, 25, 361-365.	0.5	17
231	In vivo and in vitro evaluation of [18F]FETO with respect to the adrenocortical and GABAergic system in rats. European Journal of Nuclear Medicine and Molecular Imaging, 2003, 30, 1398-1401.	3.3	35
232	Synthesis of [18F]FETO, a novel potential 11 β -hydroxylase inhibitor. Journal of Labelled Compounds and Radiopharmaceuticals, 2003, 46, 379-388.	0.5	22
233	A general method for the fluorine-18 labelling of fluoroquinolone antibiotics. Journal of Labelled Compounds and Radiopharmaceuticals, 2003, 46, 715-727.	0.5	10
234	Radiosynthesis of 3-($^{2-}$ [18F]fluoro)-flumazenil ([18F]FFMZ). Journal of Labelled Compounds and Radiopharmaceuticals, 2003, 46, 1229-1240.	0.5	12

#	ARTICLE	IF	CITATIONS
235	The labelling of Nanocoll® with [111In] for dual-isotope scanning. Applied Radiation and Isotopes, 2003, 59, 337-342.	0.7	9
236	Comparison of three different purification methods for the routine preparation of [11C] Metomidate. Applied Radiation and Isotopes, 2003, 59, 125-128.	0.7	8
237	Synthesis of fluorine-18-labeled ciprofloxacin for PET studies in humans. Nuclear Medicine and Biology, 2003, 30, 285-291.	0.3	123
238	Pharmacokinetics of 2-methoxyphenylmetyrapone and 2-bromophenylmetyrapone in rats. European Journal of Drug Metabolism and Pharmacokinetics, 1999, 24, 23-29.	0.6	0
239	Simultaneous analysis of 2-methoxyphenylmetyrapone and its seven potential metabolites by high-performance liquid chromatography. Biomedical Applications, 1997, 704, 315-323.	1.7	1
240	Spectral and chromatographic properties of 2-methoxyphenylmetyrapone and its potential metabolites. Journal of Pharmaceutical and Biomedical Analysis, 1997, 15, 479-486.	1.4	2
241	Urinary metabolic profile in rat of 1-(2-methoxyphenyl)-2-methyl-2-(3-pyridyl)-1-propanone: a potential radioligand for functional diagnosis of adrenal pathology. Xenobiotica, 1996, 26, 211-219.	0.5	3
242	Some new methods for the synthesis of cardiac neurotransmission PET radiotracers. Nuclear Medicine and Biology, 1995, 22, 1037-1043.	0.3	4
243	Metabolic and pharmacokinetic considerations in the design of 2-phenyl substituted metyrapone derivatives: 2-methoxyphenylmetyrapone as a radioligand for functional diagnosis of adrenal pathology. Nuclear Medicine and Biology, 1995, 22, 1067-1074.	0.3	11
244	The Potential Role of the MCHR1 in Diagnostic Imaging: Facts and Trends. , 0, , .		2
245	Synthesis of [68Ga]Gallium DOTA-(Tyr3)-Octreotide Acetate ([68Ga]-Dotatoc). , 0, , 321-334.		3
246	Synthesis of 2-(4-N-[11C]Methylaminophenyl)-6-Hydroxybenzothiazole ([11C]6-OH-BTA-1; [11C]PIB). , 0, , 177-189.		0
247	Synthesis of 3-Amino-4-[2-(N-Methyl-N-[11C]Methyl-Amino-Methyl)Phenylsulfanyl]-Benzonitrile ([11C]DASB). , 0, , 285-296.		0